PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2015 | 2 | 3 | 205-210
Article title

Terapia anty-VEGF w cukrzycowym obrzęku plamki

Content
Title variants
EN
Anti-VEGF treatment in diabetic macular edema
Languages of publication
PL
Abstracts
EN
Macular edema is the leading cause of considerable visual impairment in diabetic patients. Elevated levels of vascular endothelial growth factor (VEGF) in the vitreous humour play a key role in accumulation of fluid and in formation of diabetic macular edema. According to the results of multiple studies, anti-VEGF therapy with ranibizumab, bevacizumab or aflibercept proved to be more effective in improving vision in patients with decreased visual acuity due to diabetic macular edema (both in mono- and combined therapy) than laser photocoagulation. The paper presents different treatment options of anti- VEGF therapy depending on various forms of macular edema, visual acuity and previously undergone treatments to achieve the best functional results in an individual patient.
PL
Obrzęk plamki jest najczęstszą przyczyną znacznego pogorszenia widzenia u pacjentów z cukrzycą. Jednym z głównych czynników odpowiedzialnych za gromadzenie się płynu w obszarze plamkowym i powstawanie obrzęku jest wewnątrzgałkowy wzrost stężenia śródbłonkowego czynnika wzrostu naczyniowego (VEGF, vascular endothelial growth factor). Wyniki licznych badań potwierdzają lepsze efekty terapii anty-VEGF ranibizumabem, bewacyzumabem lub afliberceptem (zarówno w monoterapii, jak i terapii łączonej) w porównaniu z dotychczas stosowaną laseroterapią w zakresie poprawy ostrości wzroku u pacjentów z pogorszeniem widzenia w przebiegu cukrzycowego obrzęku plamki. Praca przedstawia możliwości leczenia inhibitorami anty-VEGF w zależności od czasu trwania i postaci obrzęku, wyjściowej ostrości wzroku oraz wcześniej stosowanych metod leczenia, w celu osiągnięcia najlepszego efektu terapii u danego pacjenta.
Discipline
Publisher
Journal
Year
Volume
2
Issue
3
Pages
205-210
Physical description
References
  • 1. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin epidemiologic study of diabetic retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009; 116(3): 497-503.
  • 2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. British Medical Journal 1998; 317: 703-713.
  • 3. Arend O, Remky A, Elsner AE, et al. Quantification of cystoid changes in diabetic maculopathy. Invest Ophthalmol Vis Sci 1995; 36(3): 608-613.
  • 4. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Archives of Ophthalmology 1985; 103(12): 1796-1806.
  • 5. Nguyen QD, Tatlipinar S, Shah SM, et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular oedema. Am J Ophthalmol 2006; 142: 961-969.
  • 6. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
  • 7. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 2005; 112: 806-816.
  • 8. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month randomized, controlled, double masked, multiceter phase II study. Diabetes Care 2010; 33: 2399-2405.
  • 9. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE Study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
  • 10. Brown DM, Nguyen QD, Marcus DM, et al.; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
  • 11. Campochiaro PA, Wykoff CC, Shapiro H, et al. Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema. Ophthalmology 2014; 121: 1783-1789.
  • 12. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI Study: phase II primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 2011; 118(9): 1819-1826.
  • 13. Korobelnik JF, Do DV, Schmidt-Erfurth U, et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 2014; 121: 2247-2254.
  • 14. Arevalo JF, Fromow-Guerra J, Quiriz-Mercado H, et al.; The Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow up. Ophthalmology 2007; 114: 743-750.
  • 15. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study) 12-month data: report 2. Ophthalmology 2010; 117: 1107-1118.
  • 16. Wells JA, Glassman AR, Jampol LM, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med 2015; 372: 1193-1203.
  • 17. Bandello F, De Benedetto U, Knutsson KA, et al. Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 2011; 5: 1303-1308.
  • 18. Elman MJ, Bressler NM, Qin H, et al.; Diabetic Retinopathy Clinical Research Network. Expanded 2 year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
  • 19. Nguyen QD, Shah SM, Khwaja AA, et al. Two year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2007; 114: 1860-1867.
  • 20. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina 2011; 31: 1009-1027.
  • 21. Sohn HJ, Han DH, Kim TI, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011; 152: 686-694.
  • 22. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116: 1142-1150.
  • 23. Synek S, Vojnikovic B. Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema. Coll Antropol 2010; 34(2): 99-103.
  • 24. Cunha-Vaz J, Ashton P, Lezzi R, et al. Sustained delivery fluocinolone acetonide vitreous implants: long term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 121: 1892-1903.
  • 25. Stewart MW. Corticosteroid use for diabetic macular edema: old fad or a new trend? Curr Diab Rep 2012; 12: 364-375.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-b984badf-0d64-4cd7-a682-89ab8368d0a7
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.